Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples by unknown
Dallol et al. J Transl Med  (2016) 14:118 
DOI 10.1186/s12967-016-0878-9
RESEARCH
Clinical significance of frequent somatic 
mutations detected by high-throughput 
targeted sequencing in archived colorectal 
cancer samples
Ashraf Dallol1,2*, Abdelbaset Buhmeida2, Mahmoud Shaheen Al‑Ahwal3,7, Jaudah Al‑Maghrabi4, 
Osama Bajouh1,5, Shadi Al‑Khayyat3, Rania Alam6, Atlal Abusanad3, Rola Turki5, Aisha Elaimi1,6, 
Hani A. Alhadrami1,6, Mohammed Abuzenadah1,6, Huda Banni1, Mohammed H. Al‑Qahtani2 
and Adel M. Abuzenadah1,2,6
Abstract 
Background: Colorectal cancer (CRC) is a heterogeneous disease with different molecular characteristics associated 
with many variables such as the sites from which the tumors originate or the presence or absence of chromosomal 
instability. Identification of such variables, particularly mutational hotspots, often carries a significant diagnostic and/
or prognostic value that could ultimately affect the therapeutic outcome.
Methods: High‑throughput mutational analysis of 99 CRC formalin‑fixed and paraffin‑embedded (FFPE) cases was 
performed using the Cancer Hotspots Panel (CHP) v2 on the Ion Torrent™ platform. Correlation with survival and 
other Clinicopathological parameters was performed using Fisher’s exact test and Kaplan–Meier curve analysis.
Results: Targeted sequencing lead to the identification of frequent mutations in TP53 (65 %), APC (36 %), KRAS 
(35 %), PIK3CA (19 %), PTEN (13 %), EGFR (11 %), SMAD4 (11 %), and FBXW7 (7 %). Other genes harbored mutations 
at lower frequency. EGFR mutations were relatively frequent and significantly associated with young age of onset 
(p = 0.028). Additionally, EGFR or PIK3CA mutations were a marker for poor disease‑specific survival in our cohort 
(p = 0.009 and p = 0.032, respectively). Interestingly, KRAS or PIK3CA mutations were significantly associated with 
poor disease‑specific survival in cases with wild‑type TP53 (p = 0.001 and p = 0.02, respectively).
Conclusions: Frequent EGFR mutations in this cohort as well as the differential prognostic potential of KRAS and 
PIK3CA in the presence or absence of detectable TP53 mutations may serve as novel prognostic tools for CRC in 
patients from the Kingdom of Saudi Arabia. Such findings could help in the clinical decision‑making regarding thera‑
peutic intervention for individual patients and provide better diagnosis or prognosis in this locality.
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Background
Colorectal cancer (CRC) is major cause of morbidity 
and mortality around the world being the third most 
common cancer type worldwide [1]. Localized statis-
tics show that the age-standardized incidence rates (per 
100,000) of CRC in KSA vary between 9.5 in females 
to 14.1 in males being the most common cancer type 
in Saudi males [1]. CRC is a heterogeneous disease 
affected by genetic and epigenetic variations acting 
as passengers or drivers of the tumor. However, com-
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mutations affecting APC [2], activating mutations of 
KRAS or BRAF oncogenes [3], deletions of the 18q [4] 
and 17p [5] chromosomal regions, microsatellite insta-
bility (MSI) [6] with deleterious mutations affecting the 
tumor suppressor genes TP53 [7]. In terms of meth-
ylation, the CpG Island Methylator Phenotype (CIMP) 
pathway is the second most common pathway in spo-
radic CRC [8].
In terms of the application of precision medicine and 
personalized oncology, it is important to identify under-
lying variations as individually or in combination as 
such understanding can potentially affect treatment. For 
example, CRC tumors with high levels of chromosomal 
instability have a poor prognosis, especially if they are in 
stage II or III [9]. Conversely, tumors with high micro-
satellite instability have a better clinical outcome com-
pared to microsatellite-stable tumors [6]. CIMP-positive 
CRC tumors are usually associated with the proximal 
colon of older females and often accompanied by BRAF 
mutations [10]. Male CRC patients who are CIMP nega-
tive and carry a polycomb target genes methylation 
signature have a favorable prognosis [11]. In terms of 
genetic mutations, KRAS mutations adversely affect 
patients’ response with anti-EGFR treatment modali-
ties [3]. Furthermore, mutations in the EGFR itself 
may cause unpredictable responses to such treatments 
[3]. Mutations in the PIK3CA or BRAF downstream 
of EGFR signaling may also adversely affect treatment 
response [3].
We have used the cancer hotspot panel version 2 from 
Life Technologies in combination with the Ion Torrent 
personal genome platform in order to investigate the 
mutational status of 2800 COSMIC (catalogue of somatic 
mutations in cancer) mutations in 50 oncogenes and 
tumor suppressor genes in a cohort of CRC cases from 
Saudi Arabia. The results obtained will help us under-
stand the genetic background of CRC from this popula-
tion and help implement relevant modalities of precision 
medicine to the treatment of this disease.
Methods
Patients
The material of the present study consist of a series 
of 99 CRC specimens, retrospectively collected from 
the archives of Anatomical Pathology Laboratory in 
King Abdulaziz University (KAUH) and King Faisal 
Specialist Hospitals (KFSHRC), Jeddah, Kingdom of 
Saudi Arabia, covering the period from January 2005 
to December 2014. Serial sections were cut from par-
affin blocks, stained with Hematoxylin and Eosin for 
routine histological examination, classification, grad-
ing and staging following the AJCC staging system [11]. 
The pertinent clinicopathological data (gender, age, 
grade, and lymph node status), and follow-up results 
were retrieved from the patients’ records after obtain-
ing the relevant ethical approvals. DNA was extracted 
from 10  μm-thin formalin-fixed paraffin-embedded 
slices using the Qiagen QIAMP Formalin-fixed Parafin-
embedded Tissue DNA extraction kit, following the 
manufacturer’s guidelines.
Ion PGM library preparation and sequencing
Approximately 10  ng of DNA from each sample, as 
determined by the Qubit assay (Life Technologies) were 
used to construct barcoded Ion Torrent adaptor-ligated 
libraries utilizing the Ion Ampliseq Library Kit 2.0 (Life 
Technologies) following the manufacturer’s protocol. 
The cancer genes were amplified in 207 amplicons using 
the primer pool from the Cancer Hotspot Panel 2.0 (Life 
Technologies). Templated spheres were prepared using 
100  pM of DNA from each library using the Ion One-
Touch 2.0 machine. Template-positive spheres from 
the barcoded libraries were multiplexed and loaded 
onto Ion chips 316 version 2.0 and sequencing was per-
formed using the Ion Sequencing 200 v2 kit from Life 
Technologies.
Variant calling
Processing of the PGM runs was achieved with the Tor-
rent Suite version 4.4.3. The Coverage information, iden-
tification of low frequency variants, as well as variant 
annotation was achieved by the Ampliseq CHPv2 sin-
gle sample workflow within the Ion Reporter suite v4.6. 
Somatic mutations with a coverage ≥100 and p value of 
≤0.05 were included. Variants with near 50/50 distribu-
tion of coverage were presumed germ line and excluded 
from further analysis. In order to increase accuracy of 
variant calling, variants not previously reported either in 
dbSNP or COSMIC databases were excluded from fur-
ther analysis.
Statistical analysis
All statistical tests were performed using IBM SPSS Sta-
tistics version 19. Fisher’s exact test was used to identify 
statistical significance of correlation between mutational 
events and clinicopathological factors. The primary end-
points of the study included disease-specific survival 
(DSS) calculated from the date of diagnosis to the last 
recorded date of being alive or death caused by CRC. In 
calculating DSS, patients who died of other or unknown 
causes were excluded. All survival times were calculated 
by univariate Kaplan–Meier analysis, and equality of 
the survival functions between the strata was tested by 
log-rank (Mantel-Cox) test. Multivariate Cox regression 
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analysis was performed to disclose independent predic-
tors of DSS. All tests were two-sided, and p-values <0.05 
were considered statistically significant.
Results
The cancer hotspot panel v2 based on the Ampliseq tech-
nology and the ion torrent PGM was utilized to screen 99 
archival FFPE samples obtained from colorectal cancer 
patients diagnosed and treated at KAUH and KFSHRC 
between 2005-2014. (Table  1) Variants identified were 
filtered based on coverage level above 100× and p-value 
of <0.05 followed by the exclusion of common variants. 
Hotspot mutations were identified in 88/99 cases occur-
ring in 41 genes at variable frequency (Table  2). Fre-
quent mutations were identified in TP53 (65  %), APC 
(36  %), KRAS (35  %), PIK3CA (19  %), SMAD4 (11  %), 
EGFR (11 %), PTEN (13 %), and FBXW7 (7 %). Less fre-
quent mutations were additionally identified in 33 other 
genes at a frequency ranging from 1 to 6  % (Fig.  1). In 
comparison to the mutation frequencies reported by the 
COSMIC database of mutations detected in cancers orig-
inating in the large intestine TP53 and EGFR mutation 
frequencies are high in our cohort. On the other hand, 
ATM and ERBB4 mutations are relatively rare. The 
remaining genes are mutated at a frequency similar to 
COSMIC reports (Fig. 2).
Ninety-five different TP53 mutations were detected 
in 64 patients (Fig.  1; Table  2) with the most com-
mon mutations affecting arginine residues 175 
(6 cases; p.Arg175His and p.Arg175Leu), 248 (6 
cases; p.Arg248Glu and p.Arg248Trp), 273 (5 cases; 
p.Arg273Cys and p.Arg273His). Furthermore, TP53 
mutations are largely concentrated in the DNA binding 
domain, but mutations affecting the other domains of the 
protein were also identified at a lesser frequency. Thirty 
mutations were found affecting the APC gene in 39 
patients. APC mutations are not concentrated in a par-
ticular domain, however, 21/30 mutations were truncat-
ing mutations (Fig. 1; Table 2). The most recurrent APC 
mutation is affecting the arginine 1450 residue (9 cases; 
p.Arg1450Ter). Nine different mutations were identi-
fied in KRAS (Fig.  1; Table  2) with the most common 
affecting glycine 12 residue (20 cases; p.Gly12Asp/Ser/
Val) followed by changes to the glycine 13 residue recur-
ring 7 times (p.Gly13Asp). The p.Ala146Thr mutation 
was identified in 5 patients while the p.Gln61His change 
was identified in two patients. Known pathogenic muta-
tions affecting SMAD4 were found in 6 patients (Fig. 1; 
Table  2). Overall there were eleven cases with somatic 
SMAD4 mutations identified in this cohort with the most 
frequent variant is the p.Arg361His missense mutation in 
occurring in 3 patients. PIK3CA mutations were identi-
fied affecting 19 patients. These mutations were largely 
occurring in Exon 9 and exon 20 of the protein (13/19 
mutations; Table  2) with changes at the glutamic resi-
dues 542 and 545 being the most frequent (6/19). Exon 
20 mutations occurred in 7/19 cases. Fifteen mutations 
were identified affecting EGFR in 11 patients (Fig. 1 and 
Table  2). One mutations was identified in the extracel-
lular receptor L domain (p.Gly109Glu) and 14/15 muta-
tions in the intracellular protein tyrosine kinase domain. 
p.Glu746Lys occurred 4 times and the p.Gly719Cys/
Ser occurring 3 times in our cohort. PTEN mutations 
were identified in 13 patients with the most common 
being p.Arg130Gln, p.Asp115Asn and p.Asp24Asn. 
The remaining mutations identified are summarized in 
Table 2.
The presence of APC mutations correlated with muta-
tions affecting the EGFR and SMAD4 genes (Pearson’s 
correlation; p = 0.016 and p = 0.002, respectively). Simi-
lar correlation is also found with SMAD4 and EGFR 
mutations (p  =  0.001). Additionally, there is a posi-
tive correlation between KRAS and PIK3CA mutations 
(p = 0.004). Positive correlation was also found between 
PIK3CA and EGFR mutations (p  =  0.019) as well as 
Table 1 Clinical features of  99 CRC patients included 
in this study
Number of cases (%)
Number of cases 99
 Males 58 (58.6)
 Females 41 (41.4)
Age
 Below 50 years old 25 (25.3)
 Above 50 years old 74 (74.7)
Tumor location
 Right colon 22 (22.2)
 Left colon 47 (47.5)
 Rectum 27 (27.3)
 Undetermined 3 (03.0)
Lymph node status
 LN+ 46 (46.5)
 LN− 41 (41.4)
 Undetermined 12 (12.1)
Grade
 Grade 1 (well‑differentiated) 16 (16.2)
 Grade 2 (moderately‑differentiated) 61 (61.6)
 Grade 3 (poorly‑differentiated) 10 (10.1)
 Undetermined 12 (12.1)
Survival status
 Recurrence 42 (42.4)
 Dead 24 (24.2)
 Alive 74 (74.7)
 Undetermined 01 (01.0)
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Table 2 Somatic mutations detected by the cancer hotspot panel v2 in CRC
Gene Mutations detected
TP53 p.Ala69Val, p.Pro72Ala, p.Pro72Ser, p.Thr81Ile, p.Pro82Leu, p.Ala84Val, p.Pro87Leu, p.Trp91Ter, p.Ser94Ter, p.Ser95Phe, p.Ser96Phe, p.Pro98Leu, 
p.Ser99Phe, p.Gln100Ter, p.Arg110Leu, p.Leu130Ile, p.Lys132Arg, p.Cys135Ter, p.Leu137Gln, p.Pro151Thr, p.Pro152Leu, p.Gly154Asp, 
p.Gly154Ser, p.Arg156His, p.Val157Ile, p.Val157Phe, p.Ala161Thr, p.Tyr163Cys, p.Gln165Ter, p.Ser166Leu, p.His168Pro, p.His168Tyr, 
p.Glu171Lys, p.Val172Ile, p.Val173Ala, p.Val173Met, p.Arg175His, p.Arg175Leu, p.Pro177Ser, p.His179Arg, p.His179Tyr, p.Cys182Tyr, 
p.Ser183Leu, p.Gly187Ser, p.Pro190 fs, p.Arg196Ter, p.Gly199Glu, p.Arg202Cys, p.Arg209 fs, p.Thr211Ile, p.Arg213Ter, p.Ser215Asn, 
p.Val216Met, p.Tyr220Asn, p.Tyr220Cys, p.Glu221Gly, p.Gly226Ser, p.Cys229Tyr, p.Tyr234Cys, p.Cys238Tyr, p.Ser240Arg, p.Ser240Asn, 
p.Gly244Asp, p.Gly245Ser, p.Met246Val, p.Arg248Gln, p.Arg248Trp, p.Arg249Ser, p.Thr253Ile, p.Glu258Gln, p.Gly266Arg, p.Gly266Glu, 
p.Arg267Gln, p.Ser269Asn, p.Glu271Lys, p.Val272Met, p.Arg273Cys, p.Arg273His, p.Cys275Phe, p.Cys277Phe, p.Gly279Glu, p.Arg280Lys, 
p.Asp281Asn, p.Arg282Trp, p.Glu285Lys, p.Glu287Lys, p.Arg290His, p.Pro300Leu, p.Pro300Ser, p.Gly302Glu, p.Arg306Ter, p.Glu336Lys, 
c.559 + 3G > C, c.560‑1G > C, c.376‑1G > A
APC p.Asn869Thr, p.Arg876Ter, p.Arg1114Ter, p.Glu1286Ter, p.Ala1296 fs, p.Ala1299Val, p.Ile1307Lys, p.Ile1307 fs, p.Glu1309Ter, p.Glu1309 fs, 
p.Ala1351Thr, p.Ser1356Ter, p.Ser1360Tyr, p.Gln1367Ter, p.Glu1374Ter, p.Gln1378Ter, p.Glu1379Ter, p.Pro1439Leu, p.Arg1450Ter, 
p.Glu1461Lys, p.Ser1465 fs, p.Leu1488 fs, p.Leu1488Ter, p.His1490Leu, p.His1490 fs, p.Ser1495 fs, p.Ser1501 fs, p.Thr1556 fs, p.Glu1576Lys, 
p.Glu1577Ter
KRAS p.Ala11Val, p.Gly12Val, p.Gly12Ser, p.Gly12Asp, p.Gly13Asp, p.Val14Ile, p.Gln22Lys, p.Gln61His, p.Ala146Thr
PIK3CA p.Arg88Gln, p.Arg108His, p.Leu339Ile, p.Asn345Lys, p.Asp350Gly, p.Cys420Arg, p.Pro539His, p.Glu542Lys, p.Glu545Asp, p.Glu545Gly, 
p.Glu545Lys, p.Gln546His, p.Arg1023Ter, p.Thr1025Ala, p.Asn1044Ser, p.His1047Arg, p.His1048Arg, p.Ala1066Thr, p.Ter1069 fs
PTEN p.Lys6Glu, p.Glu7Ter, p.Asp24Asn, p.Gln110Ter, p.Asp115Asn, p.Cys124Tyr, p.Ala126Val, p.Arg130Gln, p.Gly165Glu, p.Ser170Asn, p.Gln171Ter, 
p.Arg173Cys, p.Pro246Leu, p.Val255Ile, p.Glu256Lys, p.Pro339Ser
SMAD4 p.Arg100Met, p.Arg135Ter, p.Gln245Ter, p.Gln248Ter, p.Thr259Ile, p.Glu330Lys, p.Ser343Ter, p.Gly352Arg, p.Arg361His, p.Arg361His, 
p.Arg361His, p.Cys499Tyr, p.Arg531Gln
EGFR p.Gly109Glu, p.Gly696Arg, p.Pro699Ser, p.Gly719Ser, p.Gly719Cys, p.Gly721Ser, p.Trp731Ter, p.Glu746Lys, p.Thr751Ile, p.Ala755Thr, 
p.Glu758Lys, p.Leu858Met, p.Gly863Asp, p.Ala864Val, p.Gly873Glu
FBXW7 p.Arg465Cys, p.Arg465His, p.Met467Ile, p.Arg479Gln, p.Arg479Pro, p.Arg479Ter
BRAF p.Gly469Val, p.Gly469Ala, p.Val600Glu, p.Lys601Glu
RB1 p.Ile680Thr, p.Leu683Phe
RET p.Cys618Tyr, p.Asp627Gly, p.Glu884Val, p.Glu901Lys, p.Leu923Phe
ATM p.Val410Ala, p.Phe858Leu, p.Thr1735 fs, p.Leu2866Val
NOTCH1 p.Arg1598His, p.His1601Leu, p.Pro2438Ser, p.Gln2440Ter
STK11 p.Glu165Lys, p.Gly171Ser, p.Gly279Arg, p.Phe354Leu
KIT p.Pro37Ser, p.Arg49His, p.Asp52Asn, p.Asp572Asn
KDR p.Lys270Asn, p.Gly1145Glu, p.Pro1354Ser
CDH1 pThr342Ile, p.Thr399Ile
PTPN11 p.Glu69Lys, p.Thr73Ile, p.Glu76Lys
ERBB2 p.Met774Ile, p.Val851Met, p.Thr862Ala, p.His878Tyr
SMO p.Val404Met, p.Leu412Phe, p.Pro634Leu
CTNNB1 p.Met12Ile, p.Pro16Ser, p.Val22Ile, p.Ser37Phe
VHL p.Gln132Ter, p.Arg161Gln, p.Arg167Gln, c.341‑1G > A
CDKN2A p.Glu88Lys, p.Arg99Trp, p.Asp125Asn, p.Arg128Gln
FLT3 p.Ser446Leu, p.Lys602Arg, p.Trp603Ter
IDH2 p.Arg140Gln, p.Arg140Trp
FGFR3 p.Asp643Asn, p.Ala719Thr












Page 5 of 9Dallol et al. J Transl Med  (2016) 14:118 
PIK3CA and PTEN mutations (p = 0.008). The presence 
of PTEN mutations correlated positively with the pres-
ence of SMAD4 mutations (p = 0.015), EGFR mutations 
(p  =  0.001) as well as FBXW7 mutations (p  =  0.015). 
Furthermore, FBXW7 mutations correlated positively 
with BRAF mutations (p =  0.009). In terms of associa-
tion with clinicopathological parameters, EGFR muta-
tions were significantly associated with young age of 
onset (Fisher’s exact t-test; p = 0.028). Mutations affect-
ing BRAF are associated with tumors arising in the right 
colon (p = 0.023).
In terms of disease-specific survival (DSS), CRC 
tumors harboring KRAS mutations have shorter DSS 
prognosis (Kaplan–Meier log rank test, p  =  0.056; 
Fig.  3a). However, such prognosis is worsened if the 
patient has KRAS mutations coupled with wild-type 
TP53 (Kaplan–Meier log rank test, p =  0.001; Fig.  4a). 
Similarly, PIK3CA mutations are associated with shorter 
DSS (Kaplan–Meier log rank test, p  =  0.032; Fig.  3b). 
However, the effect of PIK3CA mutations on DSS is 
increased in the background of wild-type TP53 (Fig. 4b). 
Furthermore, EGFR mutations are associated with sig-
nificantly shorter DSS in CRC (Kaplan–Meier log rank 
test, p = 0.009; Fig. 3c). Cox’s regression analysis of dis-
ease-specific survival indicates that detection of EGFR 
mutations is an independent marker for poor prognosis 
in CRC with a hazard ratio of 3.639 (Table 3; p = 0.02, 
CI = 1.221–10.850).
Discussion
We have identified TP53 in this study as the most com-
monly mutated gene in CRC from a group of 50 genes 
included in the cancer hotspot panel v2. Although 
expected, as TP53 is a tumor suppressor protein that is 
commonly mutated in many types of cancer, the increase 
from TP53 mutations frequency as reported by COSMIC 
database [12] is noteworthy. Mutant TP53 is an emerging 
target for cancer treatment using small molecule thera-
peutics that restores wild-type TP53 function in inducing 
cell cycle arrest and apoptosis. One of such molecules is 
the PRIMA-1/APR-246 small molecule which is showing 
promising results in phase I/II clinical trials [13].
Fig. 1 Distribution of the somatic mutations identified in relations to age, tumor location, lymph node metastasis (LN) or tumor grade. A positive 
value is indicated with a black square while a negative value is indicated by a white square
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The adenomatous polyposis coli (APC) gene was the 
second most commonly mutated gene in our cohort 
with 36.4 % of the cases examined displaying missense, 
nonsense or frameshift mutations in the hotspot regions 
of this gene. The most common mutation identified was 
the p.Arg1450Ter change resulting in the expression 
of truncated APC and thus loss of control on nuclear 
β-catenin mediated gene expression and dysregulation 
of the WNT pathway. APC mutations do not exhibit 
any significant prognostic value in our cohort although 
it has been shown previously that wild-type APC may 
confer a favorable prognosis in microsatellite stable 
CRC tumors only [14]. Mutations in the TGFβ path-
way are represented by the alterations in SMAD4 in 
our cohort. Interestingly, we have detected pathogenic 
SMAD4 somatic missense variants previously reported 
in cases of juvenile polyposis syndrome [15] in 6 adult 
CRC patients. EGFR mutational rate detected in this 
study is higher than what is reported in the COSMIC 
database (11.1  % and 4  %, respectively). This relatively 
high mutation rate of EGFR in CRC may present itself 
as an opportunity for the use of the non-small cell 
lung carcinoma tyrosine kinase inhibitors (TKIs) treat-
ment regimes targeting this receptor. This finding is of 
interest as it may influence the therapeutic outcome 
of chemotherapeutic drugs such as erlotinib or gefi-
tinib [16]. PTEN is another gene that is mutated at a 
relatively high frequency in our cohort of CRC sam-
ples (13.1  %). PTEN functions as a tumor suppressor 
by negatively regulating AKT/PKB signaling pathway 
through the negative regulation of the intracellular lev-
els of phosphatidylinositol-3,4,5-trisphosphate in cells. 
PIK3CA is the other frequently mutated gene in this 
pathway and it is significantly associated with poor dis-
ease-free survival.
Conclusions
The frequent EGFR mutations identified in this cohort 
suggest an alternative therapeutic targeting avenue 
where lessons learnt from the treatment of lung cancer 
(the cancer type with the highest frequency of EGFR 
mutations detected) can be applied. In addition, high 
Fig. 2 Comparison of the mutation frequency of cancer genes (x-axis) as reported in the COSMIC database [12] (white bars) and identified in our 
CRC cohort (black bars)
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throughput targeted sequencing could reveal the inter-
play between different mutations and could elucidate 
their potential as prognostic markers as we show in 
this study for KRAS and PIK3CA mutations. Further-
more, understanding the molecular landscape of CRC 
in different populations will help in designing assays 
Fig. 3 Kaplan‑Meier survival curves showing the effects of the presence of somatic mutations in KRAS (a), PIK3CA (b) and EGFR(c) (indicated by “+” 
sign) on disease‑specific survival
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where the detection of frequently mutated genes will 
strongly indicate the presence of tumor growth, thus 
aiding easier diagnosis and large-scale screening 
programs.
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